219 related articles for article (PubMed ID: 8614294)
1. The vesamicol receptor ligand (+)-meta-[125I]iodobenzyltrozamicol [(+)-[125I]-MIBT] reveals blunting of the striatal cholinergic response to dopamine D2 receptor blockade in the 6-hydroxydopamine (6-OHDA)-lesioned rat: possible implications for Parkinson's disease.
Efange SM; Langason RB; Khare AB; Low WC
Life Sci; 1996; 58(16):1367-74. PubMed ID: 8614294
[TBL] [Abstract][Full Text] [Related]
2. Age-related diminution of dopamine antagonist-stimulated vesamicol receptor binding.
Efange SM; Langason RB; Khare AB
J Nucl Med; 1996 Jul; 37(7):1192-7. PubMed ID: 8965197
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and tissue distribution of (m-[125I]iodobenzyl)trozamicol ([125I]MIBT): potential radioligand for mapping central cholinergic innervation.
Efange SM; Michelson RH; Khare AB; Thomas JR
J Med Chem; 1993 Jun; 36(12):1754-60. PubMed ID: 8510103
[TBL] [Abstract][Full Text] [Related]
4. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
5. Sequential changes of cholinergic and dopaminergic receptors in brains after 6-hydroxydopamine lesions of the medial forebrain bundle in rats.
Araki T; Tanji H; Fujihara K; Kato H; Imai Y; Mizugaki M; Itoyama Y
J Neural Transm (Vienna); 2000; 107(8-9):873-84. PubMed ID: 11041269
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
Ztaou S; Maurice N; Camon J; Guiraudie-Capraz G; Kerkerian-Le Goff L; Beurrier C; Liberge M; Amalric M
J Neurosci; 2016 Aug; 36(35):9161-72. PubMed ID: 27581457
[TBL] [Abstract][Full Text] [Related]
7. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
[TBL] [Abstract][Full Text] [Related]
8. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
[TBL] [Abstract][Full Text] [Related]
9. Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment.
Zhang C; Steiner JP; Hamilton GS; Hicks TP; Poulter MO
J Neurosci; 2001 Aug; 21(15):RC156. PubMed ID: 11459877
[TBL] [Abstract][Full Text] [Related]
10. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine.
Dluzen D
Brain Res; 1997 Sep; 767(2):340-4. PubMed ID: 9367266
[TBL] [Abstract][Full Text] [Related]
11. In vivo extracellular recording of striatal neurons in the awake rat following unilateral 6-hydroxydopamine lesions.
Chen MT; Morales M; Woodward DJ; Hoffer BJ; Janak PH
Exp Neurol; 2001 Sep; 171(1):72-83. PubMed ID: 11520122
[TBL] [Abstract][Full Text] [Related]
12. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment.
Christopher L; Marras C; Duff-Canning S; Koshimori Y; Chen R; Boileau I; Segura B; Monchi O; Lang AE; Rusjan P; Houle S; Strafella AP
Brain; 2014 Feb; 137(Pt 2):565-75. PubMed ID: 24334314
[TBL] [Abstract][Full Text] [Related]
13. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
14. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
16. EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease.
Vorobyov VV; Schibaev NV; Morelli M; Carta AR
Brain Res; 2003 May; 972(1-2):177-85. PubMed ID: 12711091
[TBL] [Abstract][Full Text] [Related]
17. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
[TBL] [Abstract][Full Text] [Related]
18. Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET.
Nikolaus S; Larisch R; Beu M; Forutan F; Vosberg H; Müller-Gärtner HW
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):390-5. PubMed ID: 12634967
[TBL] [Abstract][Full Text] [Related]
19. Cortical stimulation induces Fos expression in striatal neurons via NMDA glutamate and dopamine receptors.
Liste I; Rozas G; Guerra MJ; Labandeira-Garcia JL
Brain Res; 1995 Nov; 700(1-2):1-12. PubMed ID: 8624698
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic input is required for increases in serotonin output produced by behavioral activation: an in vivo microdialysis study in rat forebrain.
Mendlin A; Martín FJ; Jacobs BL
Neuroscience; 1999; 93(3):897-905. PubMed ID: 10473255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
